NBP - NovaBridge Biosciences.

3.22
-0.020   -0.621%

Share volume: 505,208
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$3.24
-0.02
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 7%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.13%
1 Month
-0.62%
3 Months
-19.30%
6 Months
-21.27%
1 Year
295.09%
2 Year
75.96%
Key data
Stock price
$3.22
P/E Ratio 
0.00
DAY RANGE
$3.12 - $3.38
EPS 
N/A
52 WEEK RANGE
$0.60 - $6.79
52 WEEK CHANGE
$283.52
MARKET CAP 
91.398 M
YIELD 
N/A
SHARES OUTSTANDING 
80.883 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-27-2025
BETA 
1.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,021,546
AVERAGE 30 VOLUME 
$671,531
Company detail
CEO: Xiu X. Zhu
Region: US
Website: i-mabbiopharma.com
Employees: 380
IPO year: 2020
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

I-Mab discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases. Its product candidates also includes Enoblituzumab, which has completed Phase 2 clinical trials for head and neck cancer, and other oncology diseases.

Recent news